Avadel Pharmaceuticals (AVDL) PT Lowered to $13 at Stifel, but Maintained at Buy, Analyst Sees Latest FT218 Commentary as Good News and Expects Near Term Approval
Tweet Send to a Friend
Stifel analyst Paul Matteis lowered the price target on Avadel Pharmaceuticals (NASDAQ: AVDL) to $13.00 (from $14.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
